Prothena Corp. Plc - Ordinary Shares (MM) News - PRTAV

Prothena to Report Third Quarter 2022 Financial Results on November 3rd

Prothena to Report Third Quarter 2022 Financial Results on November 3rd DUBLIN, Ireland, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Prothena...

Prothena to Participate in Upcoming Healthcare Conferences

Prothena to Participate in Upcoming Healthcare Conferences DUBLIN, Ireland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc...

Prothena Announces Appointment of Biotechnology Industry Leader Helen S. Kim to its Board of Directors

Prothena Announces Appointment of Biotechnology Industry Leader Helen S. Kim to its Board of Directors DUBLIN, Ireland, Sept. 01, 2022...

Prothena Reports Second Quarter 2022 Financial Results and Business Highlights

Prothena Reports Second Quarter 2022 Financial Results and Business Highlights Net cash used in operating and investing activities was $35.5...

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Ireland, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Prothena...

Prothena to Report Second Quarter 2022 Financial Results on August 8th

Prothena to Report Second Quarter 2022 Financial Results on August 8th DUBLIN, Ireland, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Prothena...

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Ireland, July 01, 2022 (GLOBE NEWSWIRE) -- Prothena...

Prothena to Participate in Jefferies Healthcare Conference

Prothena to Participate in Jefferies Healthcare Conference DUBLIN, Ireland, June 02, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation...

Prothena Reports First Quarter 2022 Financial Results and Business Highlights

Prothena Reports First Quarter 2022 Financial Results and Business Highlights Net cash used in operating and investing activities was $37.4...

Prothena to Report First Quarter 2022 Financial Results on May 5th

Prothena to Report First Quarter 2022 Financial Results on May 5th DUBLIN, Ireland, April 28, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation...

Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease

Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of...

Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease

Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of...

Prothena to Participate in Stifel 2022 Virtual CNS Days

Prothena to Participate in Stifel 2022 Virtual CNS Days DUBLIN, Ireland, March 21, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation...

Prothena Presents New Data for Alzheimer’s and Parkinson’s Disease Programs at AD/PD 2022

Prothena Presents New Data for Alzheimer’s and Parkinson’s Disease Programs at AD/PD 2022 Oral presentation on preclinical data demonstrates...

Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidance and Business Highlights

Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidance and Business Highlights Net cash used...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Prothena Corp. Plc - Ordinary Shares (MM) (PRTAV)

Empower your portfolio: Real-time discussions and actionable trading ideas.

PRTAV News

Prothena to Report Third Quarter 2022 Financial Results on November 3rd

Prothena to Participate in Upcoming Healthcare Conferences

Prothena Announces Appointment of Biotechnology Industry Leader Helen S. Kim to its Board of Directors

Prothena Reports Second Quarter 2022 Financial Results and Business Highlights

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Prothena to Report Second Quarter 2022 Financial Results on August 8th

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Prothena to Participate in Jefferies Healthcare Conference

Prothena Reports First Quarter 2022 Financial Results and Business Highlights

Prothena to Report First Quarter 2022 Financial Results on May 5th

Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease

Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease

Prothena to Participate in Stifel 2022 Virtual CNS Days

Prothena Presents New Data for Alzheimer’s and Parkinson’s Disease Programs at AD/PD 2022

Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidance and Business Highlights

PRTAV Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Prothena Corp. Plc - Ordinary Shares (MM) (PRTAV) News

Prothena Corp. Plc - Ordinary Shares (MM) (PRTAV)

Empower your portfolio: Real-time discussions and actionable trading ideas.

PRTAV News

Prothena to Report Third Quarter 2022 Financial Results on November 3rd

Prothena to Participate in Upcoming Healthcare Conferences

Prothena Announces Appointment of Biotechnology Industry Leader Helen S. Kim to its Board of Directors

Prothena Reports Second Quarter 2022 Financial Results and Business Highlights

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Prothena to Report Second Quarter 2022 Financial Results on August 8th

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Prothena to Participate in Jefferies Healthcare Conference

Prothena Reports First Quarter 2022 Financial Results and Business Highlights

Prothena to Report First Quarter 2022 Financial Results on May 5th

Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease

Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease

Prothena to Participate in Stifel 2022 Virtual CNS Days

Prothena Presents New Data for Alzheimer’s and Parkinson’s Disease Programs at AD/PD 2022

Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidance and Business Highlights

PRTAV Discussion

Your Recent History